~~<i id='D86045E4B5'><strike id='D86045E4B5'><tt id='D86045E4B5'><pre id='D86045E4B5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：comprehensive 2025-08-31 16:35:10 - browse：54895

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

focus

entertainment

focus

leisure time

hotspot

knowledge

RichardPazdur,right,alsospokeabouttheFDA'suseofacceleratedapproval.MeganBearderPhotographyCHICAGO— T

WSS

Ionis drug prevents swelling attacks due to hereditary angioedema

Covid hospitalizations on the rise, Humana says

Intellia reports positive results for its CRISPR

Covid hospitalizations on the rise, Humana says

ALS advocates say criticism of new drugs misses bigger picture

Stem cell treatment guidelines are released by FDA

leisure time

fashion

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Letters to First Opinion on caregivers, digital health, and more

Walensky prepares to leave CDC — and Congress — behind

ALS advocates say criticism of new drugs misses bigger picture

Hepatitis C has a cure — but many Americans still lack access to it

Why Novartis is changing the name of its research labs

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cord blood banking comes at a high cost to babies

Drug repurposing or repositioning? The language matters

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

entertainment

The 10 drugs up first for Medicare price negotiation

The 10 drugs up first for Medicare price negotiation

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Medicaid rebukes states for mistakenly disenrolling children

Ultragenyx gene therapy for rare liver ailment succeeds in late

Change Healthcare can notify patients about the breach, HHS says

focus

leisure time

hotspot

knowledge